Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

Friday, August 29, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the TORREY open-label extension study of Seralutinib, a treatment for pulmonary arterial hypertension (PAH) in adults. It highlights the potential benefits of Seralutinib for patients suffering from this condition. The study aims to gather long-term data on the efficacy and safety of the treatment.
Price reaction · baseline $2.4 (2025-08-28 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
+2.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promise for treating pulmonary arterial hypertension.
  • The TORREY study indicates potential benefits for patients.
  • Open-label extension studies can provide valuable long-term data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib used for?

Seralutinib is used for the treatment of pulmonary arterial hypertension in adults.

What does the TORREY study focus on?

The TORREY study focuses on the open-label extension of Seralutinib for PAH.

What are the potential benefits of Seralutinib?

Seralutinib may provide significant benefits for patients with pulmonary arterial hypertension.

Is there long-term data available for Seralutinib?

The TORREY study aims to gather long-term data on the efficacy and safety of Seralutinib.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary arterial hypertension TORREY study clinical trial
Last updated: Aug 29, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →